Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
---|
02/26/2004 | WO2002038775A3 METHODS FOR PRODUCING AND PURIFYING RECOMBINANT α-L-IDURONIDASE |
02/26/2004 | WO2001074299A3 Compositions and methods for inhibition of cancer invasion and angiogenesis |
02/26/2004 | US20040039366 Injectable pharmaceutical suspension in a two-chamber vial |
02/26/2004 | US20040039356 Compositions for external preparations |
02/26/2004 | US20040039204 Compositions of n-(methylethaylaminocarbonyl)-4-(-3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosacccharides |
02/26/2004 | US20040039195 Cucurbituril derivatives, their preparation method and uses |
02/26/2004 | US20040039176 Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs |
02/26/2004 | US20040039172 Relates to immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates and method of inducing anti-HIV antibodies using such immunogen |
02/26/2004 | US20040039160 Comprises therapeutic agent, oligopeptide having an isoleucine residue, stabilizing group, and, optionally, a linker group; prodrug is cleavable by an enzyme associated with target cell; antitumor agents |
02/26/2004 | US20040039057 Putrescine, spermine, spermidine or cadaverine with urea or lidocaine |
02/26/2004 | US20040039036 Oral solution containing famotidine and edetic acid or a salt |
02/26/2004 | US20040039022 Storage stable mixtures of (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol, water, buffers and chelate compounds used as neuroprotectants |
02/26/2004 | US20040039021 Pharmaceutical anti-inflammatory aerosol formulation |
02/26/2004 | US20040039020 Novel pharmaceutical formulation suitable for nebulisation |
02/26/2004 | US20040039011 Administering anticholinergic or bronchodilator agents such as tiotropium bromide for prophylaxis of respiratory system disorders |
02/26/2004 | US20040038963 5,5-Difluoro-3(S)-(pyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-(1, 8)-naphthyridin-2-yl)-nonanoic acid; inhibition of bone resorption, restenosis, angiogenesis, retinopathy, macular degeneration, arthritis, metastatic tumor growth, etc. |
02/26/2004 | US20040038953 Medical combination comprising salmeterol and budesonide |
02/26/2004 | US20040038952 Combination of a bile acid and a bioflavonoid; also for treating eye disorders and premenstrual symptoms. |
02/26/2004 | US20040038948 Promoting healing through enhanced regeneration of hard or soft tissue contact with an anti-inflammatory agent; useful in treating periodontal diseases and in orthopedic applications. |
02/26/2004 | US20040038935 Delivery of a therapeutic agent in a formulation for reduced toxicity |
02/26/2004 | US20040038920 Which stimulate lymphoctyes specific for myelin basic protein (MBP) autoantigen, which induces severe experimental autoimmune encephalomyelitis in animal models; cytokines |
02/26/2004 | US20040038916 Delivery of a therapeutic agent in a formulation for reduced toxicity |
02/26/2004 | US20040038903 Gonadotropin releasing hormone antagonists in gel-forming concentration |
02/26/2004 | US20040038899 Polymer stabilized neuropeptides |
02/26/2004 | US20040038892 Chemically-modified human growth hormone conjugates |
02/26/2004 | US20040038885 Carriers for administration of active principles such as drugs or nutriments, cosmetic products or plant health products such as herbicides, pesticides, insecticides, fungicides, etc. |
02/26/2004 | US20040038878 Injectable protein formulations |
02/26/2004 | US20040038876 For use in therapy and diagnosis |
02/26/2004 | US20040038871 Attaching a linker to an amino group of the drug, the linker including an aldehyde or ketone carbonyl group, and forming an oxime by reaction of the carbonyl group with an O-alkylhydroxylamine derivative of the peptide |
02/26/2004 | US20040038870 Methods of drug delivery using sulphated chitinous polymers |
02/26/2004 | US20040038867 Orally administering an amount of an insulin polypeptide-oligomer conjugate to the subject for reducing hypoglycemic episodes |
02/26/2004 | US20040038866 For therapy of insulin deficiency |
02/26/2004 | US20040038864 Use of dimethyl sulfone as isotonicity agent |
02/26/2004 | US20040038859 Containing stabilizing agent comprising matrix metalloproteinase inhibitor |
02/26/2004 | US20040038424 Formaldehyde-ammonium salt complexes for the stabilization of blood cells |
02/26/2004 | US20040038410 Composition for the preservation of viruses |
02/26/2004 | US20040038406 Nanoparticle delivery systems and methods of use thereof |
02/26/2004 | US20040038339 Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
02/26/2004 | US20040038324 Epothilone resistant cell lines |
02/26/2004 | US20040038303 Comprises use of small particle with appropriate hydrophilic-lipophilic-balance value to deliver anticarcinogenic agents to cells and/or tissues; drug screening |
02/26/2004 | US20040038204 Replacing worn wear strip associated with viral and nonviral gene delivery systems; gene therapy |
02/26/2004 | US20040037907 Parenteral pimaricin as treatment of systemic infections |
02/26/2004 | US20040037897 Treatment of drug resistant organisms |
02/26/2004 | US20040037893 Aqueous composition also including a buffer to keep the pH in the range of 4.0-8.0, a salt of calcium and/or magnesium in a concentration of >15 mM; stabilised against chemical and/ or physical degradation during storage or transportation |
02/26/2004 | US20040037888 Administering intrarectally or to anorectal region aqueous gel composition containing drug effective in such treatment and carrier comprising water soluble cellulose derivative gelling agent, propylene glycol, water |
02/26/2004 | US20040037885 Amphiphilic diblock copolymer, poorly water-soluble drug, biodegradable polymer, liquid poly(ethylene glycol); composition forms implant containing drug and drug containing polymeric micelles, which are slowly released |
02/26/2004 | US20040037883 Controlled release dosage forms |
02/26/2004 | US20040037880 Extended release formulation of divalproex sodium |
02/26/2004 | US20040037879 Oral controlled release forms useful for reducing or preventing nicotine cravings |
02/26/2004 | US20040037877 Flavored gelatin capsule and method of manufacture |
02/26/2004 | US20040037875 Composition for treatment of inflammatory disorders |
02/26/2004 | US20040037874 Delivery of nucleic acid-like compounds |
02/26/2004 | US20040037873 Norethindrone sustained release formulations and methods associated therewith |
02/26/2004 | US20040037872 Active substance-containing adhesive patch comprising diclofenac or a topically acceptable salt thereof; patch composed of outer impermeable backing layer, matrix layer comprising active substance, removable protective layer |
02/26/2004 | US20040037853 Botulinum neurotoxin formulated with a recombinant serum albumin |
02/26/2004 | US20040037836 Comprises nitroglycerin; for preventing adverse effects associated with medical device implantation; for inhibiting platelet deposition; angiotensin converting enzyme inhibitors |
02/26/2004 | US20040037835 Comprises nitroreductase and nicotinamide cofactor; antitumor agents |
02/26/2004 | US20040037834 Rhamm peptide conjugates |
02/26/2004 | US20040037819 Non-polymeric hematopoeitic cell clots for delivery of active agents |
02/26/2004 | US20040037809 Intranasal delivery of interferon- beta yielding improved pharmacokinetic and pharmacodynamic results. In certain aspects of the invention, the interferon- beta is delivered to the intranasal mucosa along with one or more intranasal |
02/26/2004 | US20040037803 A G-CSF solution formulation which is substantially free from proteins as a stabilizer but which contains at least one amino acid or a salt thereof as a stabilizer. |
02/26/2004 | US20040037802 Activated polymeric bicine derivatives such as polypeptides modified with these polymers exhibit reduced immunogenicity/antigenicity and circulate in the blood |
02/26/2004 | US20040037801 Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
02/26/2004 | US20040037797 Water-in-oil emulsions containing one or more ammonium acryloylodimethyltaurate/vinylpyrrolidone copolymers |
02/26/2004 | US20040037784 Particulate (2S)-3-(4-(((4-(aminocarbonyl)-1-piperidinyl) carbonyl)oxy)phenyl)-2-(((2S)-4-methyl-2-((2-(2-methylphenoxy) acetyl)amino)pentanoyl)amino) propanoic acid or a salt or solvate thereof and one or more suitable excipients for |
02/26/2004 | US20040037783 Pharmaceutical formulation of fluticasone propionate |
02/26/2004 | US20040037778 Iodinated and/or brominated derivatives of aromatic dihydroxy monomers are prepared and polymerized to form radio-opaque polymers. The monomers may also be copolymerized with other dihydroxy monomers. The iodinated and brominated aromatic |
02/26/2004 | US20040037775 Treating and preventing autoimmune diseases. The compositions and methods utilize peptides that are cell-specific. The peptides are conjugated to drugs. The peptide-drug conjugate can be internalized by the targeted cells thereby allowing for |
02/26/2004 | DE20318634U1 Topical compositions for preventing or treating rhinitis, comprising sympathomimetic agent with vasoconstrictive and/or mucosal swelling reducing action and glycosaminoglycan to reduce side-effects |
02/26/2004 | DE20220604U1 Zusammensetzung, enthaltend feine Partikel zur Langzeitfreisetzung für schnell in der Mundhöhle zerfallende Tabletten Composition containing fine particles for sustained release of rapidly disintegrating in the oral cavity tablets |
02/26/2004 | DE20215415U1 Wasserlösliche Medikamentenvorstufen von Propofol Water-soluble prodrugs of propofol |
02/26/2004 | DE10309368A1 Pharmazeutische Zubereitung mit RNA als Cofaktor der Hämostase Pharmaceutical preparation containing RNA as a cofactor of hemostasis |
02/26/2004 | DE10238162A1 Carrier solution for foods, essential ingredients or dietetically- or pharmacologically-active materials contains a thickener |
02/26/2004 | DE10238161A1 Mucosal or topical administration of minerals, e.g. for treating muscle spasms, psoriasis or osteoporosis or promoting wound healing, comprises direct application of mineral solution from ampoule |
02/26/2004 | DE10238144A1 Use of aryl-substituted 3,6-dialkylidene-2,5-piperazinedione derivatives as photostable UV filters in cosmetic or pharmaceutical compositions for protecting human skin or hair against solar radiation |
02/26/2004 | CA2854798A1 Anti-tnf-alpha antibodies in solution and uses thereof |
02/26/2004 | CA2495389A1 Compositions and methods for the diagnosis and treatment of tumor |
02/26/2004 | CA2495345A1 Topical anhydrous and ethanol-free ascomycin compositions |
02/26/2004 | CA2494147A1 Pharmaceutical compositions for buccal delivery of pain relief medications |
02/26/2004 | CA2494132A1 Pharmaceutical composition, metered dose dispenser containing same, and use of pharmaceutical composition and metered dose dispenser in administering pharmaceutical agent to oral membranes |
02/26/2004 | CA2494002A1 Antigenic compositions |
02/26/2004 | CA2493928A1 Nucleic acids and corresponding proteins entitled 273p4b7 useful in treatment and detection of cancer |
02/26/2004 | CA2493925A1 Nucleic acids and corresponding proteins entitled 202p5a5 useful in treatment and detection of cancer |
02/26/2004 | CA2493923A1 Nucleic acids and corresponding proteins entitled 191p4d12(b) useful in treatment and detection of cancer |
02/26/2004 | CA2493921A1 Nucleic acids and corresponding proteins entitled 282p1g3 useful in treatment and detection of cancer |
02/26/2004 | CA2493748A1 Methods and compositions for treatment of macular and retinal disease |
02/26/2004 | CA2493727A1 Improved thermoplastic hydrophilic adhesive compositions for attachment on dry and wet surfaces and with increased water adhesion stability |
02/25/2004 | EP1391513A1 IL-7 drug substance, IL-7 comprising composition, preparation and uses thereof |
02/25/2004 | EP1391426A1 Method for the preparation of a silicic acid comprising extrudate, said extrudate, its use and a pharmaceutical composition comprising the said extrudate |
02/25/2004 | EP1391213A1 Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
02/25/2004 | EP1391212A1 Oral preparations and supports for oral preparations |
02/25/2004 | EP1391209A1 Protein formulations |
02/25/2004 | EP1391205A1 Pharmaceutical composition with RNA as cofactor of hemostasis |
02/25/2004 | EP1391202A1 Liquid drug preparations |
02/25/2004 | EP1391201A1 Medicinal compositions |
02/25/2004 | EP1390740A1 Methods and formulations for increasing the affinity of a 1? adenosine receptor ligands for the a 1? adenosine receptor |
02/25/2004 | EP1390518A2 Buffer solution for electroporation and a method comprising the use of the same |
02/25/2004 | EP1390495A2 Immunostimulatory oligodeoxynucleic molecules |
02/25/2004 | EP1390494A2 Method for stabilising of nucleic acids |
02/25/2004 | EP1390472A2 Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv |